Navidea Biopharmaceuticals(OTC) NAVBQ

Market Cap$100.00

Since IPO (1992)-100%

5 Year-100%

1 Year-100%

1 Month-99%

$0.00

+0.00%

+0.00Today

Navidea Biopharmaceuticals last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-09-01

Navidea Biopharmaceuticals stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-08-25
1 month	-99%	USD 0.00	2026-07-31
3 month	-99%	USD 0.00	2026-06-02
Year to date	+0%	USD 0.00	2025-12-31
1 year	-99.8%	USD 0.00	2025-08-29
3 year	-100%	USD 0.08	2023-09-01
5 year	-100%	USD 1.60	2021-09-02
Since inception	-100%	USD 130.00	1992-11-10

Navidea Biopharmaceuticals Financials at a Glance

Market Cap

$100.00

Revenue (TTM)

$610.00

Net Income (TTM)

-$1.18M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

2821.03 (High)

Dividend

$0.00

Beta (Volatility)

2821.03 (High)

Price

$0.00

Volume

3,085

Open

$0.00

Price

$0.00

Volume

3,085

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.04

Estimated Earnings Date

Aug 31, 2026

Dividend

$0.00

Beta (Volatility)

2821.03 (High)

Price

$0.00

Volume

3,085

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.04

Estimated Earnings Date

Aug 31, 2026

NAVBQ News

Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical firm focused on developing and marketing innovative diagnostic tools and therapeutic agents that utilize the immune system. The company operates primarily through its Diagnostic Substances and Therapeutic Development Programs, with a strong emphasis on its proprietary Manocept platform.

Products and Services

Manocept platform for targeted diagnostic and therapeutic applications
Diagnostic techniques including SPECT and PET imaging
Pipeline candidates for rheumatoid arthritis and other immune-related conditions

Growth Outlook

Ongoing Phase IIb trials for NAV3-35 and NAV3-32 targeting rheumatoid arthritis
Exploration of Tc99m tilmanocept for cardiovascular and infectious diseases
Potential expansion into new therapeutic areas based on immune principles

Financial Highlights

Q3 2023 net income of -$2.26 million, reflecting ongoing R&D investments
Cash and cash equivalents of $3.86 million as of September 30, 2023
Trailing twelve months revenue of $0, indicating a focus on development over sales

Navidea Biopharmaceuticals, Inc. is positioned at the forefront of biopharmaceutical innovation, particularly in the realm of immune-based diagnostics and therapeutics. The company's Manocept platform is a key differentiator, enabling targeted delivery of agents to macrophages, which is crucial for addressing various immune and inflammation-related conditions. The ongoing clinical trials for rheumatoid arthritis candidates highlight the company's commitment to advancing its pipeline and addressing significant unmet medical needs. Despite recent financial challenges, including a net loss in the latest quarter, the company maintains a robust cash position to support its research and development efforts. The focus on innovative diagnostic and therapeutic solutions, combined with a strategic approach to clinical trials, positions Navidea for potential growth in the evolving biopharmaceutical landscape. Investors may find the company's unique offerings and growth potential appealing as it continues to navigate the complexities of the healthcare market.

AI Generated • Aug 26, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Michael S. Rosol, PhD

Website

www.navidea.com

Headquarters

Dublin, OH 43017-3552, US

NAVBQ Financials

Key Financial Metrics (TTM)

Gross Margin

-259.40%

Operating Margin

-21402.08%

Net Income Margin

-23117.58%

Return on Equity

355.34%

Return on Capital

N/A

Return on Assets

-347.18%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$100.00

Shares Outstanding

100.08M

Volume

3.08K

Avg. Volume

6.86K

Financials (TTM)

Gross Profit

-$158.38K

Operating Income

-$10.18M

EBITDA

-$8.89M

Operating Cash Flow

-$9.71M

Capital Expenditure

-$193.31K

Free Cash Flow

-$9.91M

Cash & ST Invst.

$3.86M

Total Debt

$1.26M

Navidea Biopharmaceuticals Performance Analysis

Navidea Biopharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2021	2021-12-31	USD 531,513	N/A
2022	2022-12-31	USD 65,652	-87.6%

Navidea Biopharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2022-12-31	-91.9%
Q1	2023-03-31	-100.0%
Q2	2023-06-30	N/A
Q3	2023-09-30	N/A

Navidea Biopharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2021	2021-12-31	USD -0.40	N/A
2022	2022-12-31	USD -0.56	39.3%

Navidea Biopharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2022-12-31	56.0%
Q1	2023-03-31	58.9%
Q2	2023-06-30	365.5%
Q3	2023-09-30	-118.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q3 2023YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$36.03K

+71.6%

Gross Margin

0.00%

N/A

Market Cap

$100.00

N/A

Market Cap/Employee

$9.09

N/A

Employees

N/A

Net Income

-$2.26M

+60.5%

EBITDA

-$2.10M

+62.3%

Quarterly Fundamentals

Name

Q3 2023YOY CHG

Total Cash

$3.86M

-16.0%

Total Debt

$1.26M

-30.8%

Accounts Receivable

$30.87K

-80.1%

Inventory

$460.75K

+137.7%

Long Term Debt

$269.00

-100.0%

Short Term Debt

$1.26M

+4505.8%

Return on Assets

-3.47%

N/A

Return on Invested Capital

2.52%

N/A

Free Cash Flow

-$10.27M

-430.0%

Operating Cash Flow

-$10.25M

-451.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

GNBTGenerex Biotechnology Corporation

GNBTGenerex Biotechnology Corporation$0.00+0.00%

CRXMGene Biotherapeutics, Inc.

CRXMGene Biotherapeutics, Inc.$0.00+9900.00%

GLSHQGelesis Holdings, Inc.

GLSHQGelesis Holdings, Inc.$0.00+0.00%

NNMXNanomix Corporation

NNMXNanomix Corporation$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$10.38+0.11%

NVDANvidia

NVDANvidia$228.45+0.02%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$149.74+0.06%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$11.01+0.06%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$46.35+0.06%

NUNu Holdings

NUNu Holdings$15.68+0.02%

INTCIntel

INTCIntel$91.67+0.02%

Questions About NAVBQ

What is the current price of Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals is trading at $0.00 per share.

What is the 52-week range for Navidea Biopharmaceuticals?

Over the past 52 weeks, Navidea Biopharmaceuticals has traded between $0.00 and $0.04.

How much debt does Navidea Biopharmaceuticals have?

As of the most recent reporting period, Navidea Biopharmaceuticals reported total debt of $2.44M.

How much cash does Navidea Biopharmaceuticals have on hand?

Navidea Biopharmaceuticals reported $2.00M in cash and cash equivalents in its most recent financial results.

What is Navidea Biopharmaceuticals’s dividend yield?

Navidea Biopharmaceuticals does not currently have a dividend yield.

Navidea Biopharmaceuticals(OTC) NAVBQ

Navidea Biopharmaceuticals Financials at a Glance

NAVBQ News

This Week in Biotech: Actions Speak Louder Than Words

Why Navidea Biopharmaceuticals Inc. Shares Briefly Spiked Lower

Why Navidea Biopharmaceuticals Inc. Shares Jumped

Why Navidea Biopharmaceuticals, Inc. Shares Jumped

Why Navidea Biopharmaceuticals Inc. Shares Soared

3 Diagnostic Stocks That May See Sales Soar Because of Obamacare

3 Stocks to Get on Your Watchlist

The 5 Most Misdiagnosed Diseases

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Navidea Biopharmaceuticals

NAVBQ Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Navidea Biopharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NAVBQ

What is the current price of Navidea Biopharmaceuticals?

What is the 52-week range for Navidea Biopharmaceuticals?

How much debt does Navidea Biopharmaceuticals have?

How much cash does Navidea Biopharmaceuticals have on hand?

What is Navidea Biopharmaceuticals’s dividend yield?

Premium Investing Services